Effect of a DPP-4 inhibitor on vascular endothelial function in type 2 diabetic patients

Effect of a DPP-4 inhibitor on vascular endothelial function in type 2 diabetic patients - Effect of a DPP-4 inhibitor on vascular endothelial function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004746

Enrollment

Registered

2010-12-20

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic patients

Interventions

DPP-4 inhibitor Standard treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Type 2 diabetic patients 2) Patients treated with none or metformin alone or sulfonylureas alone over 12 weeks prior to the study 3) Patients with written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients with contraindications to sitagliptin use 2) The patient under insulin treatment 3) The patient under alpha-GI or Gulinide treatment 4) Women who are pregnant, possibly pregnant, or are breastfeeding 5) Patients who are determined by the lead principal investigator or contributing investigators to be unsuitable

Design outcomes

Primary

Measure	Time frame
FMD (Flow mediated dilation)	—

Secondary

Measure	Time frame
HbA1c , FPG, 1,5-AG, glycated albumin, C-peptide, Reactive Oxygen Metabolites (ROMs), adiponectin	—

Countries

Japan

Contacts

Public ContactKazunari Suzuki

Nippon Medical School Hospital Geriatric Medicine

03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026